GLIS3 and MODY: The sequencing was completed in 53 MODY patients with an unknown genetic etiology (MODYX), 5,726 non-diabetic individuals, 2,930 patients newly diagnosed with T2D and 206 patients with GADA-positive diabetes with the aim to investigate 1) if GLIS3 missense variants is involved in MODYX, 2) if rare GLIS3 missense variants increase the risk of T2D development and 3) if rare GLIS3 missense variants affect measures of glucose metabolism.